NovaBay Pharmaceuticals Q2 EPS $(1.37) Misses $(1.23) Estimate, Sales $2.40M Miss $3.15M Estimate
Portfolio Pulse from Benzinga Newsdesk
NovaBay Pharmaceuticals reported Q2 EPS of $(1.37), missing the $(1.23) estimate, and sales of $2.40M, missing the $3.15M estimate. This represents a significant increase in losses and a decrease in sales compared to the same period last year.
August 13, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NovaBay Pharmaceuticals reported Q2 EPS of $(1.37), missing the $(1.23) estimate, and sales of $2.40M, missing the $3.15M estimate. This represents a significant increase in losses and a decrease in sales compared to the same period last year.
The significant miss on both EPS and sales estimates, along with increased losses and decreased sales compared to the previous year, is likely to negatively impact NovaBay Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100